CRANBURY, N.J.--(BUSINESS WIRE)--Physicians’ Education Resource®, LLC (PER®), the leading resource for oncology and hematology continuing medical education, will produce its first livestream European webcast, “Advent of Oncology Monoclonal Antibody Biosimilars – A European Perspective” on October 27, 2017, at 2:00 p.m. GMT.
The webinar will be co-chaired by Hope S. Rugo, MD, professor of medicine, director, Breast Oncology and Clinical Trials Education, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, and Giuseppe Curigliano, MD, PhD, chair, Division of Early Drug Development at the European Institute of Oncology in Milan, Italy.
“We are very excited to launch this new virtual webcast meeting to a European audience. We are going to film it in our own state-of-the-art studio that allows us to broadcast live, in real-time, to Europe. We worked with Dr. Hope Rugo to carefully select faculty that are experts in the space and can share a collaborative opinion on the state of biosimilars and its impact on treating cancer in Europe,” said Phil Talamo, president of PER®.
There will be discussions throughout the webinar about the 20 biosimilars approved by the European Medicines Agency. The webinar is designed to educate European pharmacists and physicians about the advantages of biosimilars in terms of their potential to reduce the acquisition cost of cancer drugs, thereby increasing affordability and patient access. Focus will be on the importance of analytical studies to the development and regulatory approval of biosimilars, the concepts of immunogenicity and extrapolation of indications based on evaluation of the totality of the evidence and mechanism of action rationale, and the potential risks related the suboptimal use of biosimilars and strategies.
For registration and more information, visit www.gotoper.com/go/eurobio17pr.
Since 1995, PER® has been the educational resource of choice for live and online activities focusing on oncology and hematology. PER® provides high-quality, evidence-based activities featuring leading national and international faculty, with a focus on practice-changing advances and standards of care in treatment and disease management. Activities also include topics on emerging strategies currently under investigation, supportive care, diagnosis and staging, prevention, screening and early detection, and practice management. With the rapid advances occurring in the field of oncology, understanding how to use molecular data to diagnose and stage patients, selecting the most appropriate candidates for novel therapeutic agents, individualizing treatment based on tumor type and referring patients to clinical trials will continue to ensure the highest level of patient care is provided. PER® serves the oncology health care community, including physicians, fellows, advanced practice nurses, nurses, physician assistants, pharmacists and researchers. PER® is part of the Cranbury, N.J.-based Michael J. Hennessy Associates, Inc. family of businesses. Learn more at http://www.gotoper.com and http://www.mjhassoc.com.